文献速递慢性肾脏病血液净化与透析肾移植

局限性肾癌肾切除术后肾衰竭预测模型:肾癌风险方程

A Predictive Model for Kidney Failure After Nephrectomy for Localized Kidney Cancer: The Kidney Cancer Risk Equation.
PubMed 文献 · Am J Kidney Dis · 2023-06-30

本研究基于加拿大Manitoba队列(n=1,026)开发并外部验证了预测局限性肾癌肾切除术后肾衰竭的方程,纳入年龄、性别、eGFR、尿白蛋白肌酐比、糖尿病史和手术类型,5年AUC在开发队列为0.85(95%CI 0.78-0.92),验证队列(n=12,043)为0.86(95%CI 0.84-0.88)。

要点

  • 肾癌肾切除术后肾衰竭预测方程纳入6项易获取指标,5年AUC达0.85-0.86。
  • 开发队列中10.3%的患者术后达到肾衰竭复合终点。
  • 模型可用于术前讨论肾衰竭风险,辅助治疗决策。

核心结论

  • 外部验证的模型可简便应用于临床,术前告知局限性肾癌患者肾衰竭风险。

研究设计与样本

  • 人群水平队列研究;开发队列为加拿大Manitoba成人n=1,026(2004-2016年诊断),验证队列为加拿大Ontario患者n=12,043(2008-2018年诊断),均接受部分或根治性肾切除术。

主要发现

  • 开发队列中10.3%的患者术后达到肾衰竭(透析、移植或eGFR<15mL/min/1.73m2)。
  • 最终模型5年AUC在开发队列为0.85(95%CI 0.78-0.92),验证队列为0.86(95%CI 0.84-0.88)。

关键数值与推荐

  • 预测因子包括年龄、性别、eGFR、尿白蛋白肌酐比、糖尿病史和肾切除术类型(部分/根治)。
  • 主要结局为随访期间透析、移植或eGFR<15mL/min/1.73m2的复合终点。

临床怎么用

  • 该模型可帮助临床医生在术前讨论中量化局限性肾癌患者术后肾衰竭风险。

局限性

  • 原文述需在不同队列中进一步外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Nephrectomy is the mainstay of treatment for individuals with localized kidney cancer. However, surgery can potentially result in the loss of kidney function or in kidney failure requiring dialysis/kidney transplantation. There are currently no clinical tools available to preoperatively identify which patients are at risk of kidney failure over the long term. Our study developed and validated a prediction equation for kidney failure after nephrectomy for localized kidney cancer. STUDY DESIGN: Population-level cohort study. SETTING & PARTICIPANTS: Adults (n=1,026) from Manitoba, Canada, with non-metastatic kidney cancer diagnosed between January 1, 2004, and December 31, 2016, who were treated with either a partial or radical nephrectomy and had at least 1 estimated glomerular filtration rate (eGFR) measurement before and after nephrectomy. A validation cohort included individuals in Ontario (n=12,043) with a diagnosis of localized kidney cancer between October 1, 2008, and September 30, 2018, who received a partial or radical nephrectomy and had at least 1 eGFR measurement before and after surgery. NEW PREDICTORS & ESTABLISHED PREDICTORS: Age, sex, eGFR, urinary albumin-creatinine ratio, history of diabetes mellitus, and nephrectomy type (partial/radical). OUTCOME: The primary outcome was a composite of dialysis, transplantation, or an eGFR<15mL/min/1.73m2 during the follow-up period. ANALYTICAL APPROACH: Cox proportional hazards regression models evaluated for accuracy using area under the receiver operating characteristic curve (AUC), Brier scores, calibration plots, and continuous net reclassification improvement. We also implemented decision curve analysis. Models developed in the Manitoba cohort were validated in the Ontario cohort. RESULTS: In the development cohort, 10.3% reached kidney failure after nephrectomy. The final model resulted in a 5-year area under the curve of 0.85 (95% CI, 0.78-0.92) in the development cohort and 0.86 (95% CI, 0.84-0.88) in the validation cohort. LIMITATIONS: Further external validation needed in diverse cohorts. CONCLUSIONS: Our externally validated model can be easily applied in clinical practice to inform preoperative discussions about kidney failure risk in patients facing surgical options for localized kidney cancer. PLAIN-LANGUAGE SUMMARY: Patients with localized kidney cancer often experience a lot of worry about whether their kidney function will remain stable or will decline if they choose to undergo surgery for treatment. To help patients make an informed treatment decision, we developed a simple equation that incorporates 6 easily accessible pieces of patient information to predict the risk of reaching kidney failure 5 years after kidney cancer surgery. We expect that this tool has the potential to inform patient-centered discussions tailored around individualized risk, helping ensure that patients receive the most appropriate risk-based care.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Harasemiw O, Nayak JG, Grubic N, et al. A Predictive Model for Kidney Failure After Nephrectomy for Localized Kidney Cancer: The Kidney Cancer Risk Equation. Am J Kidney Dis. 2023. PMID: 37394174. doi:10.1053/j.ajkd.2023.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。